1349 — Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapFalling Star

Market Cap
HK$3.41bn
Enterprise Value
HK$2.16bn
Revenue
CNY709.40m

Annual income statement for Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	CAS	CAS	CAS	CAS	CAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	834	1,140	1,031	851	709
Cost of Revenue
Gross Profit	770	1,059	945	777	646
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	661	923	898	754	707
Operating Profit	173	217	133	96.3	2.39
Other Net Non Operating Costs
Net Income Before Taxes	177	216	132	97.5	5.46
Provision for Income Taxes
Net Income After Taxes	164	212	137	108	39.4
Minority Interest
Net Income Before Extraordinary Items
Net Income	165	213	138	109	39.7
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	165	213	138	109	39.7
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.166	0.203	0.133	0.108	0.041
Dividends per Share